Comfort Systems USA Inc vs Natera Inc. Common Stock — how do they compare? Comfort Systems USA Inc trades at $1,495.05 (market cap $57.25B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Comfort Systems USA Inc and Natera Inc. Common Stock are close in size by market cap, and Comfort Systems USA Inc pays a 0.22% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 42 Days and Natera Inc. Common Stock for 0 Days on average.
| FIX | NTRA | |
|---|---|---|
Market Cap | $57.25B | $57.03B |
Volume | 459,246 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $2.07K | $425.64 |
52-Week Low | $790.72 | $179.42 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $55.72B | $56.18B |
Dividend Yield | 0.22% | — |
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,626.64, down 0.7% with bearish technical signals but strong fundamentals. The company demonstrates robust earnings momentum with three consecutive quarterly beats and impressive profitability metrics including 55.29% ROE. Recent acquisition of Hunt Electric expands Western electrical scale with $250M in annualized revenue. Technical indicators show bearish momentum with support at $1,611 and resistance at $1,687.
Outlook remains positive with analyst consensus price target of $2,080 representing 28% upside potential. Key opportunities include data center infrastructure demand and modular expansion, while risks involve project execution challenges and market volatility. The stock offers growth exposure to essential AI infrastructure services with strong institutional backing.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →